McKesson (NYSE:MCK - Get Free Report) is expected to be announcing its Q1 2026 earnings results after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of $8.33 per share and revenue of $95.93 billion for the quarter. McKesson has set its FY 2026 guidance at 36.750-37.550 EPS.
McKesson (NYSE:MCK - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $10.12 earnings per share for the quarter, beating the consensus estimate of $9.83 by $0.29. The company had revenue of $90.82 billion for the quarter, compared to the consensus estimate of $94 billion. McKesson had a negative return on equity of 201.12% and a net margin of 0.92%. McKesson's quarterly revenue was up 18.9% compared to the same quarter last year. During the same period in the previous year, the business earned $6.18 earnings per share. On average, analysts expect McKesson to post $33 EPS for the current fiscal year and $37 EPS for the next fiscal year.
McKesson Trading Down 3.0%
NYSE MCK traded down $21.35 on Thursday, hitting $693.57. 1,153,226 shares of the company traded hands, compared to its average volume of 521,236. The company has a market capitalization of $86.77 billion, a price-to-earnings ratio of 26.85, a P/E/G ratio of 1.45 and a beta of 0.48. The business's 50 day moving average price is $716.92 and its 200-day moving average price is $674.88. McKesson has a 52-week low of $464.42 and a 52-week high of $737.89.
McKesson Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 1st. Shareholders of record on Tuesday, September 2nd will be issued a dividend of $0.82 per share. This is a boost from McKesson's previous quarterly dividend of $0.71. This represents a $3.28 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Tuesday, September 2nd. McKesson's payout ratio is 12.70%.
Insider Activity at McKesson
In other McKesson news, EVP Leann B. Smith sold 341 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $717.91, for a total transaction of $244,807.31. Following the sale, the executive vice president directly owned 2,800 shares of the company's stock, valued at $2,010,148. The trade was a 10.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Britt J. Vitalone sold 1,878 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $717.91, for a total value of $1,348,234.98. Following the sale, the chief financial officer directly owned 14,028 shares in the company, valued at $10,070,841.48. The trade was a 11.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 52,488 shares of company stock valued at $37,242,862 over the last ninety days. 0.08% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in McKesson stock. Caxton Associates LLP bought a new stake in shares of McKesson Corporation (NYSE:MCK - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 346 shares of the company's stock, valued at approximately $233,000. Hedge funds and other institutional investors own 85.07% of the company's stock.
Analyst Upgrades and Downgrades
MCK has been the topic of a number of recent analyst reports. Mizuho raised their price target on McKesson from $630.00 to $690.00 and gave the company a "neutral" rating in a report on Thursday, April 3rd. UBS Group raised their price target on McKesson from $708.00 to $805.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Wall Street Zen cut McKesson from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 13th. Evercore ISI raised their price target on McKesson from $760.00 to $800.00 and gave the company an "outperform" rating in a report on Wednesday, July 9th. Finally, Cfra Research cut McKesson from a "moderate buy" rating to a "hold" rating in a report on Friday, April 4th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, McKesson has a consensus rating of "Moderate Buy" and a consensus target price of $710.17.
View Our Latest Analysis on McKesson
About McKesson
(
Get Free Report)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Further Reading
Before you consider McKesson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.
While McKesson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
